Literature DB >> 20676874

Surgical strategies for adenocarcinoma of the esophagogastric junction.

Marc Schiesser, Paul M Schneider.   

Abstract

This chapter summarizes the surgical strategies for adenocarcinomas of the distal esophagus, gastric cardia, and subcardial gastric cancer invading the cardia+/-distal esophagus known as adenocarcinomas of the esophagogastric junction (AEG). The different surgical approaches according to the tumor origin, localization, and tumor stage are addressed with particular attention to the extent and type of resection and appropriate lymphadenectomy (LAD). The classification of AEG according to Siewert is helpful for the selection of the surgical strategy. While type I tumors benefit from a transthoracic en bloc esophagectomy including a two-field LAD, type II and III tumors can be treated by an extended total gastrectomy with a transhiatal resection of the distal esophagus and LAD of the lower mediastinum and the abdominal D2 compartment. Limited resections appear to be -possible for early tumor stages in selected cases of type I-III tumors.

Entities:  

Mesh:

Year:  2010        PMID: 20676874     DOI: 10.1007/978-3-540-70579-6_8

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  7 in total

Review 1.  Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: a meta-analysis.

Authors:  Ming-Tian Wei; Yuan-Chuan Zhang; Xiang-Bing Deng; Ting-Han Yang; Ya-Zhou He; Zi-Qiang Wang
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

2.  Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction.

Authors:  Jiang-Wei Xiao; Zi-Lin Liu; Peng-Cheng Ye; Ya-Jun Luo; Zhi-Ming Fu; Qin Zou; Shou-Jiang Wei
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

3.  Detection of circulating tumor cells in patients with esophagogastric or pancreatic adenocarcinoma using the CellSearch® system: An observational feasibility study.

Authors:  Tobias Piegeler; Thomas Winder; Sabine Kern; Bernhard Pestalozzi; Paul Magnus Schneider; Beatrice Beck-Schimmer
Journal:  Oncol Lett       Date:  2016-06-30       Impact factor: 2.967

4.  Short-term postoperative complications and prognostic factors in patients with adenocarcinoma of the esophagogastric junction.

Authors:  Hui Zhang; WeiJian Zhang; DeFeng Peng; JinHai Zhu
Journal:  Thorac Cancer       Date:  2018-06-21       Impact factor: 3.500

5.  Comparison of Clinicopathological Characteristics in the Patients with Cardiac Cancer with or without Esophagogastric Junctional Invasion: A Single-Center Retrospective Cohort Study.

Authors:  Hiroaki Ito; Haruhiro Inoue; Noriko Odaka; Hitoshi Satodate; Michitaka Suzuki; Shumpei Mukai; Yusuke Takehara; Tomokatsu Omoto; Shin-Ei Kudo
Journal:  Int J Surg Oncol       Date:  2013-01-10

6.  Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study.

Authors:  Hiroaki Ito; Haruhiro Inoue; Noriko Odaka; Hitoshi Satodate; Michitaka Suzuki; Shumpei Mukai; Yusuke Takehara; Hiroyuki Kida; Shin-Ei Kudo
Journal:  J Exp Clin Cancer Res       Date:  2013-01-07

7.  18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.

Authors:  Paul M Schneider; Dilmurodjon Eshmuminov; Tamara Rordorf; Diana Vetter; Patrick Veit-Haibach; Achim Weber; Peter Bauerfeind; Panagiotis Samaras; Kuno Lehmann
Journal:  BMC Cancer       Date:  2018-05-09       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.